deltatrials
Completed NA NCT00601536

Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions

A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions.

Sponsor: Roxane Laboratories

Conditions Bipolar Disorder
Interventions Lithium
Updated 6 times since 2017 Last updated: Jan 19, 2018 Started: Apr 30, 2003 Primary completion: May 31, 2003 Completion: May 31, 2003

This NA trial investigates Bipolar Disorder and is currently completed. Roxane Laboratories leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Feb 2018 — Jun 2018 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2018 [monthly]

    Completed NA

    First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Roxane Laboratories
Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Pittsburgh, United States